Background: Randomized clinical trial findings support decreased red blood cell (RBC) transfusion and short-term tolerance of in-hospital anemia. However, long-term outcomes related to changes in transfusion practice have not been described.
A nemia is common in hospitalized patients and has been independently associated with short-and long-term morbidity and mortality (1) (2) (3) (4) (5) (6) (7) . Traditionally, treatment of moderate anemia (hemoglobin levels between 7 and 10 g/dL) in hospitalized patients has included transfusion of allogeneic red blood cells (RBCs) to increase hemoglobin level (8) . However, a series of randomized clinical trials showed similar outcomes with less frequent RBC transfusion, thereby avoiding potential infectious, cardiopulmonary, and immunomodulatory complications (9 -16) . The trial results supporting a more restrictive approach have been translated into practice guidelines by multidisciplinary societies, including medical, critical care, anesthesia, and pathology specialties (17) (18) (19) (20) (21) (22) . These recommendations also play a key role in patient blood management strategies that emphasize evidence-based transfusion practice and the tolerance of anemia in addition to optimizing RBC counts and minimizing perioperative blood loss.
Within our network of community hospitals, multidisciplinary patient blood management programs for specific clinical departments (such as cardiac and orthopedic surgery) were implemented beginning in 2010 (23, 24) . Strategies focused on identification and treatment of suboptimal iron stores before surgery, increased use of cell salvage and hemostatic agents (such as tranexamic acid), and blood-sparing approaches to medical and surgical procedures. These department-specific initiatives were supported by hospital-and system-level quality improvement projects to improve blood use more broadly. System-level initiatives included promotion of evidence-based transfusion practice through peer review and clinical decision support within electronic order sets for blood transfusion.
We found that a substantial reduction in RBC use was not associated with changes in 30-day or hospital mortality rates, consistent with short-term safety findings of randomized clinical trials and other observational studies (23) (24) (25) (26) (27) . However, the effect of restrictive transfusion practice on anemia persistence and longerterm clinical outcomes has not been well described (28, 29) .
In this study, we examined the incidence and prevalence of anemia in an integrated health care delivery system at and within 6 months of hospital discharge after implementation of blood management initiatives in our network. We hypothesized that an increase in moderate anemia would not adversely affect subsequent RBC transfusion, rehospitalization, or mortality events after hospital discharge.
METHODS

Design Overview
We conducted a retrospective cohort study using electronic health record data from Kaiser Permanente Northern California (KPNC), which serves 4 million members. We included all adult nonobstetric KPNC patients who were hospitalized and discharged alive from 21 hospitals during the 5 years from 1 January 2010 through 31 December 2014. The KPNC Institutional Review Board approved this study.
Sample
We identified all hospitalizations of adult patients. Patients were eligible if they survived an overnight inpatient hospital stay and were discharged from a KPNC hospital. We excluded patients who were hospitalized for observation or 1-day surgery that did not result in an overnight stay. We also excluded hospitalizations for childbirth; however, women who were hospitalized for postdelivery complications were included.
Definition of Anemia
We determined the presence and magnitude of anemia by using hemoglobin levels measured by the clinical laboratory during inpatient and outpatient care. We used the World Health Organization criteria for anemia, defined as a hemoglobin value of less than 12 g/dL in women and less than 13 g/dL in men (30). Hemoglobin levels below these thresholds but greater than 10 g/dL were defined as mild anemia. Moderate anemia was defined as a hemoglobin level less than 10 g/dL but greater than or equal to 7 g/dL. On the basis of RBC transfusion guidelines, severe anemia was defined as a hemoglobin level less than 7 g/dL (22). Home  78  90  79  91  SNF  20  9  19  8  Hospice  2  1  2  1 COPS2 = Comorbidity Points Score, version 2; IQR = interquartile range; LAPS2 = Laboratory Acute Physiology Score, version 2; RBC = red blood cell; SNF = skilled nursing facility. * Reported at the time of initial hospital discharge. Included are unique patients discharged alive with moderate (defined as hemoglobin levels ≥7 to <10 g/dL), mild (defined as hemoglobin levels ≥10 g/dL), or no anemia but not those discharged with severe anemia (defined as hemoglobin levels <7 g/dL) in 2010 (n = 164) or 2014 (n = 335). † A longitudinal, diagnosis-based score. Scores <50 are associated with hospital mortality rates <2%, whereas scores >100 are associated with rates ≥5%. ‡ Higher scores indicate increasing degrees of physiologic derangement. The univariate association between LAPS2 and mortality is such that scores <50 are associated with mortality rates <1.5%, whereas scores >125 are associated with rates between 10% and ≥15%. § Initial inpatient location on hospital entry. ͉͉ Indicates patients received a transfusion or prescription for anticoagulation within 6 mo of hospitalization.
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We defined admission hemoglobin as the lowest hemoglobin level within 72 hours before hospital entry or the most recent hemoglobin level within 30 days before an elective admission. We defined discharge hemoglobin as the most proximate hemoglobin level before hospital discharge and postdischarge hemoglobin as the initial hemoglobin level after hospital discharge.
Outcomes
Rates of RBC transfusion, rehospitalization, and mortality within 6 months of hospitalization were calculated for each patient discharged alive with moderate anemia. Resolution of anemia was assessed by examining all available hemoglobin levels within 6 months of hospital discharge, referencing the highest value during that period. Transfusion events were identified from blood bank transfusion records and included both inpatient and outpatient encounters. Rehospitalization and mortality rates were linked from admission records and death indices, respectively.
Covariates
We classified patients as having emergency or elective admission according to whether they were admitted through the emergency department. We classified hospitalizations as medical or surgical admission by the presence or absence of surgical procedural codes during hospitalization. We defined hospital entry as the time of initial admission to a non-emergency department inpatient location, including the general medical-surgical wards, transitional care unit, intensive care unit, and operating room.
To categorize patient diagnoses and comorbid conditions, we grouped International Classification of Diseases, Ninth Revision, diagnosis codes by using Health Care Utilization Project (www.ahrq.gov/data /hcup) single-level and multilevel Clinical Classifications Software categories. We quantified comorbid disease burden using the Charlson Comorbidity Index and Comorbidity Points Score, version 2, which is based on patients' medical diagnoses within the 12 months before hospitalization (31-33). We quantified illness severity at admission with the Laboratory-based Acute Physiology Score, version 2, which is based on laboratory test results, vital signs, and neurologic status within 72 hours before hospital entry.
Statistical Analysis
Descriptive analyses are presented as counts and percentages, medians and interquartile ranges, or proportions and 95% CIs. We used 2 tests for equal proportion or Wilcoxon rank-sum tests to test differences. For uncorrelated outcomes, we compared trends in dichotomous and continuous variables by using the 2 test for linear trend (Cochran-Armitage) and linear regression, respectively.
Anemia prevalence and incidence were calculated at the hospitalization and patient levels, respectively. For anemia prevalence calculations, all patients who survived hospitalization and had moderate anemia at hospital discharge were included in the numerator, whereas the denominator was all inpatients discharged alive from the hospital. For anemia incidence calculations, each patient was counted once annually-with the number of patients with moderate anemia in the numerator and all patients who survived hospitalization in the denominator. Therefore, separate admissions of individual patients were included in anemia prevalence calculations and in different years for incidence calculations. For all patients discharged alive with moderate anemia, we examined annual trends in RBC transfusion characteristics (receipt of inpatient RBC transfusion, pretransfusion hemoglobin level, number of RBC units received) as well as resolution of anemia within 6 months of discharge. We used a generalized estimating equation (GEE) to account for correlated observations and included continuous year as a covariate to test for time trends. For dichotomous (receipt of inpatient RBC transfusion) and continuous (pretransfusion hemoglobin level and number of RBC units received) outcomes, we used the modified log-Poisson and identity-Normal GEE link functions, respectively (34, 35). For the multicategory outcome (resolution of anemia), we used GEEs for nominal multinomial responses assuming a baseline category logit model (36). We selected the correlation structure of the GEE models by using a goodness-of-fit measure, QIC (quasi-likelihood under the independence model criterion). We reported results for dichotomous outcomes as risk ratios (RRs), continuous outcomes as mean change in outcome, and multicategory outcomes as odds ratios, all with corresponding 95% CIs.
Among patients discharged alive with moderate anemia, we examined the adjusted annual prevalence of RBC transfusion, rehospitalization, and mortality within 1 and 6 months of hospitalization. We used the aforementioned modified log-Poisson GEE approach and included continuous year, number of hospitalizations, age, sex, emergency admission, surgical status, Charlson Comorbidity Index score, and severity of illness (Laboratory Acute Physiology Score, version 2) as covariates. In parallel to the model of 6-month mortality in patients with moderate anemia, we fit a modified log-Poisson GEE model for this outcome by using the same covariates for all other patients (those with mild or no anemia who survived hospital discharge).
Last, we examined patient-level trends in unadjusted 6-month mortality after the first hospital discharge with moderate anemia in subgroups based on age, sex, emergency or elective surgical or medical status, presence of anemia on admission, prior RBC transfusion or anticoagulation, principal discharge diagnosis, and individual hospital site. For these patient-level observations, we used the 2 test for linear trend (Cochran-Armitage).
Two-sided P values less than 0.050 were considered statistically significant. Statistical analyses were performed by using Stata, version 14.1 (StataCorp); SAS, version 9.4 (SAS Institute); and R, version 3.4.1 (The R Foundation).
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RESULTS
From 2010 to 2014, 801 261 hospitalizations occurred among 445 371 patients who survived to discharge. Moderate anemia at hospital discharge was present in 119 489 unique patients (27%) and 187 440 hospitalizations (23%) (Appendix Table 1 , available at Annals.org). Severe anemia at hospital discharge occurred in 1219 unique patients (0.3%) and 1331 hospitalizations (0.2%). In our cohort of patients with moderate anemia, the median number of hospital discharges with anemia was 1 (interquartile range, 1 to 2) (Appendix Table 2 , available at Annals.org) and 45% of repeated hospitalizations (30 629 of 67 951) occurred within 6 months of the initial hospital discharge.
From 2010 to 2014, small changes were observed in patient characteristics at the time of study entry; however, these occurred without clinically relevant differ- 
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ences in anemia at initial hospital admission. Patients discharged with moderate anemia were older, had a higher comorbidity burden and more severe illness, and had a longer hospital stay than those with mild or no anemia ( Table 1) . Changes during the study period in the cohort with anemia included a small increase in comorbidity burden, illness severity, and emergency admissions and a decline in surgical admissions ( Table  1 and Appendix Table 3 , available at Annals.org). However, the presence and severity of anemia at the time of index hospital admission did not change clinically over the study period, nor did they vary significantly on the basis of previous 6-month hospitalization status (Appendix Tables 4 and 5 , available at Annals.org). From 2010 to 2014, the total number of RBCs transfused in the inpatient and outpatient settings decreased by more than 25% (39.8 to 28.5 RBC units per 1000 patients) (Figure) and median pretransfusion hemoglobin levels decreased from 8.2 g/dL to 7.2 g/dL ( Table 6 , available at Annals.org).
In parallel with decreased RBC transfusions from 2010 to 2014, the prevalence and incidence of anemia after hospitalization increased ( Table 2 ). The prevalence of moderate anemia at hospital discharge (n = 187 440 hospitalizations) increased during the study period (from 20% to 25% of annual hospitalizations) (RR, 1.070 [CI, 1.066 to 1.074]; P < 0.001). The annual incidence of anemia also increased at the time of hospital discharge (RR, 1.048 [CI, 1.046 to 1.051]; P < 0.001) and within 6 months of hospitalization (Tables 2 and 3). We found that most patients discharged with moderate anemia had an incremental rise in their "postdischarge" hemoglobin level (Appendix Table 7 , available at Annals.org). Despite evidence of hemoglobin recovery after hospital discharge, moderate anemia was less likely to have completely resolved within 6 months of hospitalization in 2014 than in 2010 (34% vs. 42%) ( Table 3) .
Over the study period, annual trends in outcomes related to recurrent hospital discharges with anemia paralleled those after the initial hospitalization (Appendix Table 8 Table 9 , available at Annals.org).
Subgroup analysis found no significant differences in unadjusted 6-month mortality when examined by patient demographics, hospital facility, prior transfusion or anticoagulant use, or preexisting anemia status (Appendix Table 10 , available at Annals.org). However, after stratification by comorbidity burden, modest decreases in unadjusted 6-month mortality were observed in patients with moderate anemia who had medical rather than surgical conditions (Appendix Table 11 , available at Annals.org). These decreases were most apparent in patients with infectious and circulatory diseases, possibly because of concomitant initiatives for these conditions.
DISCUSSION
In our cohort, the incidence and prevalence of moderate anemia at discharge and within 6 months of hospitalization rose over the study period. This increase coincided directly with changes in RBC transfusion practice in the management of anemia as well as secular increases in age and comorbid conditions among our hospitalized patient population. We did not detect an adverse effect of increased anemia at hospital discharge or afterward on 6-month rates of RBC transfusion, rehospitalization, or mortality. In fact, risk-adjusted mortality in patients with moderate anemia decreased over the study period in parallel with patients with mild or no anemia. 
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In hospitalized patients, anemia often is multifactorial, commonly resulting from bleeding, repeated phlebotomy, and blunted erythropoiesis associated with acute illness (37-39). The rationale for treating anemia has been based on 2 lines of evidence. Anemia has been believed to be physiologically deleterious, requiring a compensatory increase in cardiac output to maintain systemic oxygen delivery (40, 41). Furthermore, anemia has been associated with a poorer prognosis for various conditions, including cancer, chronic kidney disease, and congestive heart failure (4, 42). Thus, it has been assumed that anemia warrants correction, especially in older patients with cardiovascular disease, despite limited evidence showing benefit.
However, randomized clinical trial data show that less frequent RBC transfusion is safe in hospitalized patients with moderate anemia. The results of these clinical trials are the basis for patient blood management programs that emphasize pre-and perioperative optimization of hemoglobin levels but also tolerance of progressive degrees of anemia (43). In our cohort, these perioperative strategies seem to have reduced the number of elective surgical patients discharged with moderate anemia. Conversely, changes in clinical practice have resulted in an increase in medical and nonelective surgical patients being discharged with moderate anemia.
Strong evidence exists that moderate anemia is safe in the hospital setting, where hemodynamics and oxygen delivery can be monitored and optimized (14, 15) . However, with care of conditions initially requiring hospitalization increasingly being transitioned to outpatient management, concern has arisen that anemia related to more restrictive transfusion practice may contribute to adverse outcomes after hospital discharge (44 -46). Available clinical trials have focused predominantly on short-term interventions and hospital outcomes, not on downstream clinical events. In contrast, our study provides data showing that an increase in anemia persistence after hospitalization did not seem to adversely affect measures of morbidity and mortality in the 6 months after hospital discharge. Furthermore, clinical trial data have focused on specific admission conditions or patient populations and may not include analyses of subgroups (such as patients receiving anticoagulation or those with a history of blood transfusion) who may be at increased risk for adverse outcomes related to anemia. In our cohort, these risk factors were not associated with worsened outcomes after reduction in RBC transfusion. Our findings also are consistent with a recently published clinical trial that was the first to show that discharge anemia in cardiac surgery patients was not associated with differences in 6-month rehospitalization or mortality events (29). These growing data provide reassurance to hospital clinicians who must decide whether to discharge patients with anemia.
The translation of clinical trial findings to practice recommendations has been promoted by the American Board of Internal Medicine's Choosing Wisely campaign, in which several specialty societies have partnered to identify tests, procedures, or treatments offered to patients despite an absence of evidence demonstrating benefit (47-50). However, the Choosing Wisely campaign has not developed a structural mechanism to evaluate the impact of its recommendations on clinical practice and patient outcomes. Despite trends in anemia persistence, most patients in our study had an increase in hemoglobin levels after hospital discharge, probably related to increased bone marrow production of RBCs in concert with resolution of RBC loss from gastrointestinal bleeding and reduced phlebotomy. Our findings add to the evidence for efficacy and safety in longitudinally applying transfusion practice recommendations and tolerating anemia in a diverse community hospital population.
Because the effect of persistent anemia on quality of life is likely to be substantial and directly proportional to anemia severity, additional studies will be needed to provide guidance in anemia management, in relation not only to mortality but also to exercise tolerance in specific populations, such as those with acute (51) . These methods for treating anemia are shown to improve health-related quality of life and distance ambulated in specific populations (52-54). Although guidelines exist for the use of such treatments as intravenous iron and erythropoietin-stimulating agents, these therapies are not routinely used outside the hospital setting, except in patients having hemodialysis or those with myelodysplastic syndrome. A systematic effort to identify and treat anemia by using approaches other than transfusion is under way within our network of community hospitals. Our findings should be interpreted in light of the study's limitations. We conducted a retrospective analysis of electronic data collected in the course of routine clinical care. Although our patient population reflects the regional community practice of adults at 21 medical centers in northern California, it may not reflect clinical practice and outcomes in other community or tertiary care hospitals, pediatric age groups, or specific populations (such as transplant and obstetrics). Over the study period, we found that risk-adjusted mortality in patients with anemia declined in parallel with that of populations without anemia. We acknowledge that risk adjustment methodologies may not adequately account for unmeasured confounding, nor does the observational nature of the study allow one to establish causality. Other initiatives to improve care in both inpatients and outpatients with common conditions (such as cardiovascular disease and sepsis) occurred contemporaneously with implementation of patient blood management programs and may explain declines in overall risk-adjusted mortality and unadjusted mortality rates for these specific conditions (55-58).
In conclusion, we report increasing incidence and persistence of moderate anemia in hospitalized patients associated with a concomitant decline in RBC transfusion. Increased tolerance of moderate anemia did not seem to adversely affect long-term RBC transfusion events, rehospitalization, or mortality. In addition, reductions in risk-adjusted mortality were similar in patients with anemia and those without it. These data support the efficacy and safety of practice recommendations to limit RBC transfusion in patients with anemia during and after hospitalization. † Numbers indicate the number of hospitalizations in which patients survived with available discharge Hb levels, and percentages indicate the proportion of Hb levels among the total number of hospitalizations. ‡ Numbers indicate the number of hospitalizations in which patients had available Hb levels within 6 months of hospital discharge, and percentages indicate the proportion of Hb levels among the total number of hospitalizations. § Indicates the time after discharge at which the 6-month Hb level was obtained. P for trend = 0.47. ͉͉ Indicates the number of hospitalizations in which patients with moderate anemia had available Hb levels within 6 months of hospital discharge. ¶ Indicates the time after hospital discharge at which the 6-month Hb level was obtained in patients with moderate anemia. P for trend = 0.114. ** Indicates the highest Hb level in patients with moderate anemia within 6 months of index hospitalization. P for trend <0.001. 
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